BR9814830A - Método de redução de desejo em mamìferos - Google Patents

Método de redução de desejo em mamìferos

Info

Publication number
BR9814830A
BR9814830A BR9814830-3A BR9814830A BR9814830A BR 9814830 A BR9814830 A BR 9814830A BR 9814830 A BR9814830 A BR 9814830A BR 9814830 A BR9814830 A BR 9814830A
Authority
BR
Brazil
Prior art keywords
mammals
desire
reduction method
mammal
desire reduction
Prior art date
Application number
BR9814830-3A
Other languages
English (en)
Inventor
Vicki Coffin
Paul W Glue
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR9814830A publication Critical patent/BR9814830A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>"MéTODO DE REDUçãO DE DESEJO EM MAMìFEROS"<D>. é revelado um método de redução de desejo em um mamífero por comida ou por uma substância viciadora. O método compreende a administração ao mamífero de uma quantidade eficaz de um antagonista de D~ 1~/D~ 5~ ou de um agonista parcial de D~ 1~/D~ 5~ sozinho ou em combinação com outros compostos de CNS especificados.
BR9814830-3A 1997-10-28 1998-10-26 Método de redução de desejo em mamìferos BR9814830A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95921397A 1997-10-28 1997-10-28
PCT/US1998/022255 WO1999021540A2 (en) 1997-10-28 1998-10-26 Method of reducing craving in mammals

Publications (1)

Publication Number Publication Date
BR9814830A true BR9814830A (pt) 2000-10-03

Family

ID=25501785

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814830-3A BR9814830A (pt) 1997-10-28 1998-10-26 Método de redução de desejo em mamìferos

Country Status (16)

Country Link
EP (1) EP1043980A2 (pt)
JP (1) JP2001520989A (pt)
KR (1) KR20010031470A (pt)
CN (1) CN1283116A (pt)
AR (1) AR015984A1 (pt)
AU (1) AU1110099A (pt)
BR (1) BR9814830A (pt)
CA (1) CA2308453A1 (pt)
CO (1) CO4970824A1 (pt)
HU (1) HUP0100115A2 (pt)
IL (1) IL135659A0 (pt)
NO (1) NO20002149L (pt)
PE (1) PE122299A1 (pt)
SK (1) SK5812000A3 (pt)
WO (1) WO1999021540A2 (pt)
ZA (1) ZA989786B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1058551A1 (en) * 1998-03-02 2000-12-13 Schering Corporation Use of d1/d5 antagonists for treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders and autism
US6410527B1 (en) * 1998-03-02 2002-06-25 Schering Corporation Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism
US6890951B2 (en) 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US6395783B1 (en) 2000-10-23 2002-05-28 Brookhaven Science Associates, Llc Treatment of PCP addiction and PCP addiction-related behavior
US6462084B1 (en) 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
DK1441708T3 (da) 2001-11-05 2009-07-06 Krele Pharmaceuticals Llc Sammensætninger og fremgangsmåder til forögelse af föjelighed med terapier ved anvendelse af aldehyddehydrogenase-inhibitorer og behandling af alkoholisme
US20130165511A1 (en) 2010-09-01 2013-06-27 TONIX Pharmaceuticals Holding Corp Treatment for cocaine addiction
HRP20251123T1 (hr) 2012-07-12 2025-11-21 Emalex Biosciences, Inc. Ekopipam za liječenje touretteovog sindroma
US9949983B2 (en) * 2013-10-18 2018-04-24 Psyadon Pharmaceuticals, Inc. Fused benzazepines for treatment of stuttering
CN110327350B (zh) * 2019-07-11 2021-02-23 温州医科大学 多巴胺d1受体拮抗剂sch39166在作为制备治疗眼部病理性血管新生药物的应用
CN110833621A (zh) * 2019-12-06 2020-02-25 中国医科大学 多巴胺受体1拮抗剂在制备治疗对氯胺酮致小鼠类精神分裂症药物上的应用
WO2025194153A1 (en) 2024-03-15 2025-09-18 Emalex Biosciences, Inc. Pharmaceutical dosage forms and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607967A (en) * 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
CA2257084A1 (en) * 1996-06-06 1997-12-11 Anthony H. Cincotta Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists

Also Published As

Publication number Publication date
CO4970824A1 (es) 2000-11-07
CA2308453A1 (en) 1999-05-06
WO1999021540A2 (en) 1999-05-06
EP1043980A2 (en) 2000-10-18
NO20002149L (no) 2000-06-26
HUP0100115A2 (hu) 2001-06-28
CN1283116A (zh) 2001-02-07
WO1999021540A3 (en) 1999-09-02
ZA989786B (en) 1999-04-28
JP2001520989A (ja) 2001-11-06
IL135659A0 (en) 2001-05-20
KR20010031470A (ko) 2001-04-16
AR015984A1 (es) 2001-05-30
AU1110099A (en) 1999-05-17
PE122299A1 (es) 1999-12-04
NO20002149D0 (no) 2000-04-27
SK5812000A3 (en) 2000-12-11
WO1999021540B1 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
NO980729D0 (no) Fremganngsmåte for å nedsette syreinnholdet i råolje
HUP0104696A3 (en) Pharmaceutical composition containing 5ht1 receptor agonists and metoclopramide for the treatment of migraine
NO961223L (no) Öket korrosjonsbeskyttelse ved bruk av friksjonsreduksjonsmidler i forbindelse med korrosjonsinhibitorer
DE69434891D1 (de) Verwendung von NMDA-Antagonisten zur Behandlung von Schmerzen
BG102668A (en) Application of ppar-alpha and prar-gamma antagonist for the treatment of syndrome x
EP1109542A4 (en) NITROSED AND NITROSYLATED ANTAGONISTS OF THE ALPHA ADRENERGIC RECEPTOR, COMPOSITIONS AND USES THEREOF
BR9910180A (pt) Composição farmacêutica, processos para o tratamento de uma condição associada com a transmissão reduzida de nicotina, para identificação de um modulador positivo de um agonista receptor nicotìnico e para identificação de um composto, composto, e, uso de um modulador positivo de um agonista receptor nicotìnico
NZ505193A (en) Opioid agonist/antagonist combinations
IL135951A0 (en) Antimutagenic compositions for the treatment and prevention of photodamage to skin
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
BR9814040A (pt) Agudo no pulmão com fibrose com antagonistas de avb6
BR9908598A (pt) 20-ceto-11beta-arilesteróides e seus derivados tendo propriedades hormonais agonistas ou antagonistas
PL315653A1 (en) Application of 4-chloro-5-(imidazolyn-2-ylamino)-6-methoxy-2-methylpyrimidine and i1 agonist as pharmaceutic agents and pharmaceutic agent as such
BR9810634A (pt) Composições detergente lìquidas estruturadas,contendo ácido graxo, não-aquosas
AU5716898A (en) Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer&#39;s disease
KR870003974A (ko) 비시클로 치환된 페닐아세토니트릴 유도체
NZ333723A (en) A synergistic combination of an insulin resistance improving agent and an angiotensin II receptor antagonist or an angiotensin converting enzyme inhibitor
HUP9900037A3 (en) Use of rar-gamma antagonist or alfa-rar-alfa agonist ligands to prepare pharmaceutical compositions for reducing apoptosis
BR0113321A (pt) Combinação farmacêutica de antagonistas de angiotensina ii e inibidores da enzima conversora de angiotensina i
BR9712283A (pt) Método para inibir as cinases de proteìnas ativadas por tensão
EP0832650A3 (en) Use of serotonin 5-HT1F agonists for the prevention of migraine
WO2002028862A3 (en) Triptolide analogs for the treatment of autoimmune and inflammatory disorders
WO1999021540A3 (en) Method of reducing craving in mammals
AU5146096A (en) Compositions for treatment of photodamaged skin comprising a n rar-alpha antagonist and a multi-selective retinoid
WO2000000490A3 (en) 5-ht1f agonists

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]